An occlusive dressing containing betamethasone valerate 0.1% for the treatment of prurigo nodularis

J Dermatolog Treat. 2010 Nov;21(6):363-6. doi: 10.3109/09546630903386606.

Abstract

Introduction: Prurigo nodularis is a distressing condition characterized by the presence of multiple nodules associated with intense pruritus.

Objective: To assess the clinical efficacy and safety of betamethasone valerate 0.1% tape and a moisturizing itch-relief cream in prurigo nodularis.

Methods: Twelve patients were enrolled in this pilot comparison of betamethasone valerate 0.1% tape versus a moisturizing itch-relief cream containing feverfew. The study period was 4 weeks. Clinical evaluation was performed weekly.

Results: Eleven subjects completed the 4 weeks of therapy. The mean visual analogue scale (VAS) for pruritus at baseline was 8.75 for both sides of the body. The side treated with betamethasone valerate 0.1% tape showed a higher clinical response (VAS score at week 4: 3.9; p < 0.005) compared with the side treated with moisturizing itch-relief cream (VAS score at week 4: 5.6; p < 0.005).

Conclusion: Both treatments were effective. However, the occlusive dressing enhanced the efficacy of the treatment, preventing scratching.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Aged
  • Antipruritics / adverse effects
  • Antipruritics / chemistry
  • Antipruritics / therapeutic use*
  • Betamethasone Valerate / adverse effects
  • Betamethasone Valerate / chemistry
  • Betamethasone Valerate / therapeutic use*
  • Emollients / adverse effects
  • Emollients / chemistry
  • Emollients / therapeutic use*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Occlusive Dressings*
  • Phytotherapy / methods
  • Pilot Projects
  • Prurigo / drug therapy*
  • Surgical Tape*
  • Tanacetum parthenium
  • Treatment Outcome

Substances

  • Antipruritics
  • Emollients
  • Betamethasone Valerate